Products for Research Use Only

Longdaysin

CAT: 0804-HY-18285-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18285-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively[1][2].
CAS Number
1353867-91-0
UNSPSC
12352005
Hazard Statement
H315, H319
Target
Casein Kinase; CDK; ERK; Wnt
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/longdaysin.html
Purity
99.83
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
FC(F)(F)C1=CC=CC(CNC2=NC=NC3=C2N=CN3C(C)C)=C1
Molecular Formula
C16H16F3N5
Molecular Weight
335.33
Precautions
H315, H319
References & Citations
[1]Griffett K, et al. The mammalian clock and chronopharmacology. Bioorganic & Medicinal Chemistry Letters, 2013, 23 (7) :1929-1934..|[2]Hirota T, et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 2010 Dec 14;8 (12) :e1000559.|[3]Xiong Y, et al. Longdaysin inhibits Wnt/β-catenin signaling and exhibits antitumor activity against breast cancer. Onco Targets Ther. 2019 Feb 5;12:993-1005.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK7; CK1; ERK2